anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The patients staying in ICU for more than 24 hours were enrolled in the study. Patients received anti-inflammatory drugs or corticosteroids before admission, patients had immunosuppressive illness, patients had chronic organ failure; patients received massive blood transfusion; patients with radiation therapy and patients with previous organ transplantation were excluded from the study. At admission, patient's age, sex, weight and height were recorded. Patients data that include the clinical status; sequential organ failure assessment (SOFA) score; temperature; heart rate; respiratory rate; blood pressure; central venous pressure; laboratory analysis (complete blood count, blood urea nitrogen, blood sugar, serum sodium, potassium, calcium, aspartate aminotransferase, alanine aminotransferase, prothrombin time, albumin and CRP) and arterial blood gas analysis were measured. Routine cultures of suspected sites, blood and urine were obtained to determine the presence of infection. We attempted to maintain the patient hemoglobin level at 10-12g/dl and central venous pressure at 8-12 cmH2o. When needed, intravascular fluid replacement, blood products and inotropic or vasopressor agents were administered. Each day the attending physician evaluated all the study patients for sepsis, severe sepsis, or septic shock as long as their stay in ICU.
Treatment will be determined according to the physician's experience and Directions for Use. Cohort 1 will have follow-up on-site visits, including 3D imaging, at Months 1, 3, 6, and 12.
BACKGROUND: Intra-oral halitosis (IOH) is bad breath produced locally by the mouth in addition to systemic diseases and is one of the main causes of interpersonal communication and psychological disorders in modern society. However, current treatment modalities still only alleviate IOH and do not eradicate it. Therefore, based on the differential performance of oral microecology in IOH patients, we propose a microbiota transplantation treatment aimed at restoring oral microecological balance and analyze its feasibility by oral flora colonization test in Wistar rats.
OBJECTIVE: Saliva flora samples were collected from IOH patients and healthy subjects to analyze the feasibility of oral microbiota transplantation (OMT) for the treatment of IOH by the Wistar rat oral flora colonization test.
METHODS: Seven patients with IOH who visited the First Affiliated Hospital of Xinjiang Medical University from June 2017 to June 2022 with the main complaint of halitosis and three healthy subjects were randomly selected. A Halimeter portable breath detector was used to record breath values and collect saliva flora samples. Sixteen SPF-grade male Wistar rats were housed in the Animal Experiment Center of Xinjiang Medical University and randomly divided into an experimental group (Group E) and a control group (Group C) for the oral flora colonization test. Species composition and associated metabolic analysis of oral flora during the Wistar rat test using 16SrRNA sequencing technology and PICRUSt metabolic analysis. Also, the changes in the breath values of the rats were recorded during the test.
RESULTS: The proportion of Porphyromonas, Fusobacterium, Leptotrichia, and Peptostreptococcus was significantly higher in group E compared to group C after colonization of salivary flora of IOH patients (all P < 0.05), and the abundance with Gemella was zero before colonization, while no colonization was seen in group C after colonization compared to baseline. PICRUSt metabolic analysis also showed significantly enhanced IOH-related metabolic pathways after colonization in group E (all P < 0.05), as well as significantly higher breath values compared to baseline and group C (all P < 0.0001). After colonization by salivary flora from healthy subjects, group E rats showed a decrease in the abundance of associated odor-causing bacteria colonization, a reduction in associated metabolism, and a significant decrease in breath values. In contrast, group C also showed differential changes in flora structure and breath values compared to baseline after salivary flora colonization of IOH patients.
CONCLUSIONS: OMT for IOH is a promising green treatment option, but the influence of environmental factors and individual differences still cannot be ignored.
BACKGROUND: MicroRNA (miRNA)-based therapies have shown great potential in myocardial repair following myocardial infarction (MI). MicroRNA-302 (miR302) has been reported to exert a protective effect on MI. However, miRNAs are easily degraded and ineffective in penetrating cells, which limit their clinical applications. Exosomes, which are small bioactive molecules, have been considered as an ideal vehicle for miRNAs delivery due to their cell penetration, low immunogenicity and excellent stability potential. Herein, we explored cardiomyocyte-targeting exosomes as vehicles for delivery of miR302 into cardiomyocyte to potentially treat MI.
METHODS: To generate an efficient exosomal delivery system that can target cardiomyocytes, we engineered exosomes with cardiomyocyte specific peptide (CMP, WLSEAGPVVTVRALRGTGSW). Afterwards, the engineered exosomes were characterized and identified using transmission electron microscope (TEM) and Nanoparticle Tracking Analysis (NTA). Later on, the miR302 mimics were loaded into the engineered exosomes via electroporation technique. Subsequently, the effect of the engineered exosomes on myocardial ischemia and reperfusion (I/R) injury was evaluated in vitro and in vivo, including MTT, ELISA, real-time quantitative polymerase chain reaction (PCR), western blot, TUNNEL staining, echocardiogram and hematoxylin and eosin (HE) staining.
RESULTS: Results of in vitro experimentation showed that DSPE-PEG-CMP-EXO could be more efficiently internalized by H9C2 cells than unmodified exosomes (blank-exosomes). Importantly, compared with the DSPE-PEG-CMP-EXO group, DSPE-PEG-CMP-miR302-EXO significantly upregulated the expression of miR302, while exosomes loaded with miR302 could enhance proliferation of H9C2 cells. Western blot results showed that the DSPE-PEG-CMP-miR302-EXO significantly increased the protein level of Ki67 and Yap, which suggests that DSPE-PEG-CMP-miR302-EXO enhanced the activity of Yap, the principal downstream effector of Hippo pathway. In vivo, DSPE-PEG-CMP-miR302-EXO improved cardiac function, attenuated myocardial apoptosis and inflammatory response, as well as reduced infarct size significantly.
CONCLUSION: In conclusion, our findings suggest that CMP-engineered exosomes loaded with miR302 was internalized by H9C2 cells, an in vitro model for cardiomyocytes coupled with potential enhancement of the therapeutic effects on myocardial I/R injury.
Lactating women (up to 20 subjects) who present with clinical symptoms indicative of influenza will be recruited (a maximum of 6 months period of recruitment) to receive immediate treatment with oseltamivir (Tamiflu® 75 mg hard capsules, provided free of charges for the study) at a standard dose of 75 mg twice daily. These subjects will have a 12 hour pharmacokinetic plasma, urine and breast milk study undertaken after the steady state in oseltamivir concentrations (both active and inactive metabolites will be measured) is reached in blood, i.e. after three days after treatment.
All the study participants will receive the same treatment. 3.9g of E-EPA in capsules, which include 75µg of D3-vitamin, daily for 30 days.
Participants undergoing osseous reconstructive surgery (RegOS) for bone neoplasm. Study visits for post-op assessments will be annually after month-36.
PURPOSE: A cosmetic composition containing Taxodium distichum and Viburnum sargentii for. Sterile extract is provided to ensure excellent whitening and antioxidation. CONSTITUTION: A cosmetic composition for skin whitening and antioxiation contains 0.001-5 wt% of Viburnum sargentii for. Sterile and Taxodium distichum extract. The extract is isolated using water, alcohol of 1-4 carbon atoms, butylenes glycol, propylene glycol, glycerin, or mixture thereof. The cosmetic composition is manufactured in the form of a skin softener, nutrition lotion, nutrition cream, massage cream, nutrition serum, essence, or pack.
The present invention discloses a Chinese traditional herb medicine for tonsillitis and application of sophora fruit in the production of medicine for tonsillitis. The present invention is mainly used for treating acute tonsillitis and peritonsillar abscess. The present invention is characterized in that sophora fruit is used as raw materials to be made into oral liquid according to the following method: the sophora fruit is taken; water with 15 times of weight is added; secondary decoctions are respective 1 hour, and secondary filtered liquor is filtered, collected and merged for standby. The medicine of the present invention has the advantages of quick action and short treatment time. 52% of people who take 300 ml medicine is radically cured, and 43% of people who take 600 ml medicine is radically cured. The effective rate is 100%; the total radical cure rate reaches to 95%, and any adverse reaction is not provided.
The invention discloses a medicament for treating psoriasis. The medicament consists of the following raw material medicaments by weight: 15-29g of garlic, 20-44g of fresh leaves of broussonetia papyrifeta and 5-15ml of juice of broussonetia papyrifeta peel. A preparation method of the medicament comprises the following steps of: peeling the garlic; mashing the garlic, the fresh leaves of broussonetia papyrifeta and the juice of broussonetia papyrifeta peel together into paste; and externally applying. The garlic has bactericidal, insecticidal and antidotal effects and can be externally applied to promote blood circulation of skin, remove aging cutin of the skin, softening the skin and enhancing skin elasticity; and the fresh leaves of broussonetia papyrifeta and the juice of broussonetia papyrifeta peel have antibacterial, blood cooling, wind dispelling and uresis promoting effects. When the three medicaments are used together, the psoriasis treatment effect of the fresh leaves of broussonetia papyrifeta and the juice of broussonetia papyrifeta peel can be enhanced by the garlic; the fresh leaves of broussonetia papyrifeta and the juice of broussonetia papyrifeta peel can also be used for eliminating negative effect of the garlic on skin redness and blistering; and thus, the medicament provided by the invention has bactericidal and insecticidal functions and the functions of cooling blood and invigorating blood circulation, dispelling wind and promoting uresis, and treating ringworm sores, pain and itching. The medicament has the advantages of no negative effect, readily available materials, low treatment cost and simple preparation method.
BACKGROUND: Osteonecrosis of the femoral head (ONFH) affects both young and old patients. However, outcomes following total hip arthroplasty (THA) for these patients may vary with age. This study aimed to examine the effect of age on THA outcomes for non-traumatic ONFH patients, an area currently lacking research.
METHODS: Patients who had non-traumatic ONFH undergoing THA with at least 2 years of follow-up were identified using a database and divided into four groups by age. Then, 4 matched control groups of patients who had hip osteoarthritis (OA) were created. Multivariate logistic regression analyses were used to evaluate the rates of medical and surgical complications. Additionally, cohorts with a minimum 5-year follow-up were filtered to obtain further data on surgical outcomes. The study analyzed 85,462 non-traumatic ONFH and 80,120 hip OA patients undergoing THA.
RESULTS: Multiple medical complications in ONFH patients increased with age. Periprosthetic fracture within 2 years increased with age, while 90-day wound complications, 2-year periprosthetic joint infections, dislocations, and revisions decreased. The trends for complications continued at the 5-year follow-up. Compared to OA patients, those who had ONFH had higher risks of most complications, but this discrepancy decreased with age.
CONCLUSIONS: In ONFH patients undergoing THA, medical complications generally rise with age, while most surgical complications, including revisions, decrease. It is notable that ONFH patients experienced more complications than those who had OA, but this difference diminished with age.
PURPOSE:To provide a fat transfusion solution containing eicosapentaenoic acid or its ester as an active component, and useful as a transvenous nourishing agent, an antithrombic agent, etc. CONSTITUTION:The objective fat transfusion solution contains eicosapentaenoic acid or its ester selected from triglyceride of eicosapentaenoic acid and eicosapentaenoic acid ethyl ester. It has been ascertained that the fat transfusion solution exhibits the blood platelet coagulation inhibiting activity by transvenous administration, and the solution can be used not only as a well-balanced nutritive transfusion but also as a remedying transfusion accompanying arteriosclerosis. The eicosapentaneoic acid is e.g. fish oil such as sardine oil, cod oil, cuttle oil, etc., especially preferably a refined fish oil having low side effect to the living body. The transfusion solution can be prepared by dispersing fat, refined egg yolk lecithin and glycerol in distilled water for injection, and emulsifying the dispersion under pressure.
The invented prescription consists of (by wt. portion) root of memnranous milk vetch 30-60, rhizome of large-headed atractylodes 10-15, ledebouriella root 6-10, prepared rhizome of rehmannia 15-24, Chinese angelica 10-15, licorice root 10-15, white stiff silkworm 10-15, root bark of the tree peony 10-12 etc. 13 kinds of traditional Chinese medicinal herbs. The preparative process consists extracting volatile oil-decocting-concentrating-pelletizing. Said invention is specially designed for treating the sterility of anti-spermo-antibody, the cure rate comes up over 90%. It possesses of the efficacies of invirgorating qi, strengthening yin, and relieving the poison of blocking.
The invention relates to an Aplyzanzine A derivative, a preparation method and applications thereof, and belongs to the technical field of pharmaceutical synthesis. The invention aims to solve the problem that few compounds of Aplyzanzine A compounds have antibacterial activity. The invention provides a derivative of Aplyzazine A compounds, a preparation method and applications thereof. According to the preparation method, in the presence of a condensing agent, a compound represented by the formula (II) reacts with a compound represented by the formula (III) to obtain the final product namely the Aplyzanzine A derivative represented by the formula (I). The provided Aplyzanzine A derivative is a novel compound, has a high antibacterial activity, can well inhibit staphylococcus aureus and escherichia coli, and can be used to prepare drugs with an antibacterial activity. The provided compound can be synthesized in one step, and the preparation method has the advantages of simple technology and easy operation, and can be applied to industrial production.
This invention relates to (pharmaceutical) compositions comprising a combination of SSAO substrates and pharmaceutically acceptable compounds of the VIa and VIb group of the periodic table, i.e. selenium (VI)-, molybdenum (VI)- and tungsten (V)/(VI) compounds, etc. and to their use as insulin mimetics, i.e., to treat illness Diabetes mellitus, Obesity, or their symptoms. A here discovered synergism between the compounds of the Vla and Vlb groups of the periodic table, i.e. selenium (VI)-, molybdenum (VI)- and tungsten (V)/(VI) compounds, etc. and the SSAO substrates makes the effective concentration of the compounds of the VIa and VIb groups of the periodic table in the (pharmaceutical) composition one order of magnitude lower than the corresponding compound of the VIa and VIb groups alone. Consequently the inventive (pharmaceutical) composition has much lower toxicity than the known compounds or compositions in the art alone, what is a crucial advantage of the former for its use in the treatment and/or prevention of Diabetes mellitus, particularly of Diabetes type 2, or Obesity.
Although there is still controversy regarding why ischemic episodes are symptomatic in some patients and completely asymptomatic in others, it is now widely accepted that silent ischemia, like symptomatic episodes, negatively affects prognosis. Silent ischemia may occur in totally asymptomatic patients without (type I) or with a history (type II) of an ischemic cardiac event and coexists with symptomatic episodes in many patients (type III). However, there is a lack of data on the prognostic importance of silent ischemia in totally asymptomatic subjects without history of coronary artery disease (CAD), i.e. silent ischemia type I, and, particularly, on a possible benefit of medical therapy in such patients. Reasons lie in the difficulty to identify such patients and their expected low event rates implying that large patient populations and/or long follow-up periods would be necessary to come to definite conclusions. Still, to address this problem, we perform SWISSI 1 which includes totally asymptomatic subjects older than 40 years of age without any history of CAD but one cardiovascular risk factor with documented silent ischemia. They are randomized to open antianginal drug therapy and risk factor control versus only risk factor management and followed up for ≥ 10 years.
PURPOSE: A glucose-free pineapple extract is provided to promote tranglutaminase-1 production and to suppress melanin production. CONSTITUTION: A glucose-free pineapple extract is prepared by extracting an edible part of a pineapple by solvent and removing glucose and fructose. The solvent is 70-100 vol% ethanol solution. A laminin-5 production promoting agent contains the extract. An epidermia hyaluronic acid production promoting agent contains the extract. A melanin production inhibitor contains the extract.
To improve access to evaluation and treatment, the investigators will be offering remote cortical visual impairment clinics to assess children for cortical visual impairment. The cortical visual impairment clinics will be organized in public spaces such as school buildings, libraries, and/or hospital clinics. Study staff will contact potential clinics, buildings, etc., about interest in hosting these remote clinics. The cortical visual impairment clinics will be staffed by at least one of the following individuals: an ophthalmologist and/or an optometrist, a technician, and an occupational therapist. All participants will attend 4 remote cortical visual impairment clinics during the study. Prior to the initial clinic visit, the participants will be randomized into either the waitlist control group or the intervention group using the list of patients scheduled for the clinic. During the initial clinic visit, each child who has been given parental consent will complete both an eye exam (either an ophthalmologist or an optometrist) and functional vision evaluation with an occupational therapist. Both the eye exam and the functional vision evaluation occurring during the clinic visit are the same as would be provided during routine clinical care. None of the examinations provided during this research study will be billed through insurance. Those who are diagnosed with cortical visual impairment will continue on with the study. The intervention group will complete the telehealth intervention sessions and the waitlist control group will continue with standard care. All participants will attend three additional cortical visual impairment Clinics: one 4 months after the initial evaluation (+/- 2 weeks), one 8 months after initial evaluation (+/- 2 weeks) and another 12 months after the initial evaluation (+/- 2 weeks). During the final three cortical visual impairment clinics, the participants will complete and updated Cortical Visual Impairment Range and Canadian Occupational Performance Measure with the occupational therapist.
The invention relates to a hemorrhagic fever with renal syndrome (HFRS) nose drop or aerosol vaccine. According to the invention, traditional injection is changed into nasal mucosa administration. The development is an important innovation and out-breaking of vaccine immunization approach. The innovative source of the invention is that: type I and II viruses separated from HFRS patient early acute whole blood and Rattus norvegicus are adopted as virus seed; the virus seed is successfully adapted to Vero cells, and is subjected to massive proliferation; multi-column tandem chromatography methods such as Matrex Cellufine Sulfate affinity chromatography and Sepharose4FF gel filtration are invented; and through vector screening optimization, the HFRS aerosol vaccine with the nasal mucosa administration approach is prepared. Also, a HN-2012JZQ aerosol vaccination gun is developed. According to animal tests, the vaccine has immunogenicity and immune reactivity. The invention provides important application basis theoretical accordance for large-scale production of simple and safe aerosol vaccines which are convenient to use.
Recent studies have shown that novel antibody-drug conjugates (ADCs) can improve clinical outcomes in patients with HER2-low breast cancers. This study aimed to investigate alteration of HER2 status during breast cancer progression with an emphasis on HER2-low status. Using 386 paired samples of primary and recurrent breast cancers, HER2 discordance rate between primary and matched recurrent samples, the relationships between HER2 discordance and clinicopathological characteristics and clinical outcomes of the patients were analyzed. HER2 discordance rate between primary breast cancer and first recurrence was 25.9% (κ = 0.586) with mostly zero-to-low (10.6%) or low-to-zero (9.3%) conversion. There was no significant difference in the discordant rates according to type or location of the recurrence. Of 70 cases with a second recurrence, HER2 discordance rate between the primary tumor and the second recurrence was 27.1% (κ = 0.554). HER2 discordance was associated with lower HER2 level, lymphovascular invasion, and progesterone receptor positivity of the primary tumor. In further analyses, HER2-zero-to-low conversion was associated with lymph node metastasis and hormone receptor (HR) positivity, whereas HER2-low-to-zero conversion was associated with HR negativity and triple-negative subtype. In survival analyses, HER2 discordance was associated with decreased overall survival of patients in the HR-positive group but not in the HR-negative group. Furthermore, patients with HER2-low-to-zero converted tumors showed worse overall survival compared with those with HER2-low concordant tumors. In conclusion, HER2 status changes during breast cancer progression in significant proportions, mostly between zero and low status. As HER2 instability increases during progression and affects clinical outcome, HER2 status needs to be reevaluated in recurrent settings.
This is a single-arm, open-label, multicenter, Phase 2 clinical trial to evaluate the efficacy and safety of Brentuximab vedotin as a single agent in patients with relapsed or refractory PMLBCL who have previously received a first line of treatment with chemotherapy or immunotherapy.20 patients will be treated in this study and All patients will receive 1.8 mg/kg Brentuximab vedotin administered as a single outpatient IV infusion on Day 1 of each 21-day treatment cycle. Patients may continue on study treatment until disease progression or unacceptable toxicity. Patients who achieve stable disease or better as assessed by investigator should receive a minimum of 8, but no more than 16 cycles of study treatment.